Metagenomi (MGX) Posts Q3 Loss, Falls Short of Revenue Projections
Quarterly Performance: Metagenomi reported a quarterly loss of $0.55 per share, slightly better than the expected loss of $0.60, but worse than a loss of $0.45 per share a year ago. The company also posted revenues of $8.66 million, missing estimates by 6.44%.
Stock Performance: Metagenomi shares have declined by approximately 40.4% since the start of the year, contrasting with a 16.2% gain in the S&P 500. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Outlook: The consensus EPS estimate for the upcoming quarter is -$0.50 on revenues of $9.26 million, while the fiscal year estimate is -$2.39 on $30.44 million in revenues. The mixed trend in earnings estimate revisions could influence future stock performance.
Industry Context: The Medical - Drugs industry, to which Metagenomi belongs, is currently ranked in the top 33% of Zacks industries, suggesting a favorable environment for stocks in this sector. Another company in the same industry, Nutriband Inc., is expected to report a significant loss in its upcoming results.
Trade with 70% Backtested Accuracy
Analyst Views on MGX
About MGX
About the author
OPENAI CFO SARAH FRIAR ANNOUNCES PARTICIPATION OF A16Z, D.E. SHAW VENTURES, MGX, TPG, AND T. ROWE PRICE IN FUNDING ROUND
Funding Round Announcement: OpenAI, along with several venture capital firms including C.F.O. Sarah Friar, is participating in a new funding round.
Investors Involved: The funding round includes notable investors such as 16Z, D.E. Shaw Ventures, MGX, TPG, and T. Rowe Price.
Metagenomi Reports FY Earnings with Significant Revenue Decline
- Earnings Report: Metagenomi's FY GAAP EPS stands at -$2.36, aligning with market expectations, yet the overall performance fails to boost investor confidence amid challenging market conditions.
- Revenue Decline: The company reported revenue of $25.2 million, reflecting a significant 51.8% year-over-year decline, missing the market estimate of $28.43 million, indicating severe operational challenges.
- Market Reaction: The revenue miss is likely to negatively impact Metagenomi's stock price, as investor confidence in the company's future growth potential diminishes in light of disappointing financial results.
- Industry Context: With increasing competition in the health tech sector, Metagenomi must implement effective strategies to restore growth and enhance its market share to navigate these turbulent times.
Biotech Claims Amazon's Alexa Chips Outperform Nvidia in Disease Combatting Capabilities
Amazon's AI Advancements: Amazon has surpassed competitors like Nvidia in using AI for disease treatment, with biotech firm Metagenomi switching to Amazon's Inferentia 2 chips for gene-editing technology, citing significant cost and speed advantages.
Metagenomi's Gene-Editing Approach: Metagenomi employs CRISPR technology to edit genes, aiming to treat diseases at the genetic level rather than just alleviating symptoms, although its stock has seen a 20% decline this year.
Chardan Capital Maintains Buy on Metagenomi, Lowers Price Target to $11
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates
Quarterly Performance: Metagenomi reported a quarterly loss of $0.54 per share, better than the expected loss of $0.68, but down from a loss of $0.29 per share a year ago. The company also posted revenues of $8.51 million, exceeding estimates by 20.50%, although this is a decline from $20.01 million in the previous year.
Market Outlook: Despite underperforming the market with a 49.3% drop in shares since the beginning of the year, Metagenomi holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. Future stock movements will depend on earnings estimate revisions and industry outlook, as the Medical - Drugs sector ranks in the top 35% of Zacks industries.
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Eli Lilly's Acquisition of Verve Therapeutics: Eli Lilly has agreed to acquire Verve Therapeutics for $10.50 per share, totaling approximately $1 billion, with potential additional payments bringing the total to $1.3 billion. The deal is expected to close in Q3 2025 and represents a significant premium over Verve's recent stock price.
Market Impact and Analyst Reactions: Analysts view the acquisition as a positive validation for the gene editing sector, despite downgrading Verve's stock. They believe the deal benefits Verve shareholders and strengthens Eli Lilly's position in the genetic medicines market, which has faced challenges recently.
OPENAI CFO SARAH FRIAR ANNOUNCES PARTICIPATION OF A16Z, D.E. SHAW VENTURES, MGX, TPG, AND T. ROWE PRICE IN FUNDING ROUND
Funding Round Announcement: OpenAI, along with several venture capital firms including C.F.O. Sarah Friar, is participating in a new funding round.
Investors Involved: The funding round includes notable investors such as 16Z, D.E. Shaw Ventures, MGX, TPG, and T. Rowe Price.
Metagenomi Reports FY Earnings with Significant Revenue Decline
- Earnings Report: Metagenomi's FY GAAP EPS stands at -$2.36, aligning with market expectations, yet the overall performance fails to boost investor confidence amid challenging market conditions.
- Revenue Decline: The company reported revenue of $25.2 million, reflecting a significant 51.8% year-over-year decline, missing the market estimate of $28.43 million, indicating severe operational challenges.
- Market Reaction: The revenue miss is likely to negatively impact Metagenomi's stock price, as investor confidence in the company's future growth potential diminishes in light of disappointing financial results.
- Industry Context: With increasing competition in the health tech sector, Metagenomi must implement effective strategies to restore growth and enhance its market share to navigate these turbulent times.
Biotech Claims Amazon's Alexa Chips Outperform Nvidia in Disease Combatting Capabilities
Amazon's AI Advancements: Amazon has surpassed competitors like Nvidia in using AI for disease treatment, with biotech firm Metagenomi switching to Amazon's Inferentia 2 chips for gene-editing technology, citing significant cost and speed advantages.
Metagenomi's Gene-Editing Approach: Metagenomi employs CRISPR technology to edit genes, aiming to treat diseases at the genetic level rather than just alleviating symptoms, although its stock has seen a 20% decline this year.
Chardan Capital Maintains Buy on Metagenomi, Lowers Price Target to $11
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates
Quarterly Performance: Metagenomi reported a quarterly loss of $0.54 per share, better than the expected loss of $0.68, but down from a loss of $0.29 per share a year ago. The company also posted revenues of $8.51 million, exceeding estimates by 20.50%, although this is a decline from $20.01 million in the previous year.
Market Outlook: Despite underperforming the market with a 49.3% drop in shares since the beginning of the year, Metagenomi holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. Future stock movements will depend on earnings estimate revisions and industry outlook, as the Medical - Drugs sector ranks in the top 35% of Zacks industries.
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Eli Lilly's Acquisition of Verve Therapeutics: Eli Lilly has agreed to acquire Verve Therapeutics for $10.50 per share, totaling approximately $1 billion, with potential additional payments bringing the total to $1.3 billion. The deal is expected to close in Q3 2025 and represents a significant premium over Verve's recent stock price.
Market Impact and Analyst Reactions: Analysts view the acquisition as a positive validation for the gene editing sector, despite downgrading Verve's stock. They believe the deal benefits Verve shareholders and strengthens Eli Lilly's position in the genetic medicines market, which has faced challenges recently.
